These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 35846380)

  • 1. Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants.
    Chiuppesi F; Zaia JA; Faircloth K; Johnson D; Ly M; Karpinski V; La Rosa C; Drake J; Marcia J; Acosta AM; Dempsey S; Taplitz RA; Zhou Q; Park Y; Ortega Francisco S; Kaltcheva T; Frankel PH; Rosen S; Wussow F; Dadwal S; Diamond DJ
    iScience; 2022 Aug; 25(8):104745. PubMed ID: 35846380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stimulation of Potent Humoral and Cellular Immunity via Synthetic Dual-Antigen MVA-Based COVID-19 Vaccine COH04S1 in Cancer Patients Post Hematopoietic Cell Transplantation and Cellular Therapy.
    Chiuppesi F; Ortega-Francisco S; Gutierrez MA; Li J; Ly M; Faircloth K; Mack-Onyeike J; La Rosa C; Thomas S; Zhou Q; Drake J; Slape C; Fernando P; Rida W; Kaltcheva T; Grifoni A; Sette A; Patterson A; Dempsey S; Ball B; Ali H; Salhotra A; Stein A; Nathwani N; Rosenzweig M; Nikolaenko L; Al Malki MM; Dickter J; Nanayakkara DD; Puing A; Forman SJ; Taplitz RA; Zaia JA; Nakamura R; Wussow F; Diamond DJ; Dadwal SS
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Synthetic Multiantigen MVA Vaccine COH04S1 Protects Against SARS-CoV-2 in Syrian Hamsters and Non-Human Primates.
    Chiuppesi F; Nguyen VH; Park Y; Contreras H; Karpinski V; Faircloth K; Nguyen J; Kha M; Johnson D; Martinez J; Iniguez A; Zhou Q; Kaltcheva T; Frankel P; Kar S; Sharma A; Andersen H; Lewis MG; Shostak Y; Wussow F; Diamond DJ
    bioRxiv; 2021 Sep; ():. PubMed ID: 34545366
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates.
    Chiuppesi F; Nguyen VH; Park Y; Contreras H; Karpinski V; Faircloth K; Nguyen J; Kha M; Johnson D; Martinez J; Iniguez A; Zhou Q; Kaltcheva T; Frankel P; Kar S; Sharma A; Andersen H; Lewis MG; Shostak Y; Wussow F; Diamond DJ
    NPJ Vaccines; 2022 Jan; 7(1):7. PubMed ID: 35064109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthetic multiantigen MVA vaccine COH04S1 and variant-specific derivatives protect Syrian hamsters from SARS-CoV-2 Omicron subvariants.
    Wussow F; Kha M; Kim T; Ly M; Yll-Pico M; Kar S; Lewis MG; Chiuppesi F; Diamond DJ
    NPJ Vaccines; 2023 Mar; 8(1):41. PubMed ID: 36928589
    [TBL] [Abstract][Full Text] [Related]  

  • 6. COH04S1 and beta sequence-modified vaccine protect hamsters from SARS-CoV-2 variants.
    Wussow F; Kha M; Faircloth K; Nguyen VH; Iniguez A; Martinez J; Park Y; Nguyen J; Kar S; Andersen H; Lewis MG; Chiuppesi F; Diamond DJ
    iScience; 2022 Jun; 25(6):104457. PubMed ID: 35634578
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus.
    Chiuppesi F; Zaia JA; Gutierrez-Franco MA; Ortega-Francisco S; Ly M; Kha M; Kim T; Dempsey S; Kar S; Grifoni A; Sette A; Wussow F; Diamond DJ
    Commun Med (Lond); 2024 Feb; 4(1):19. PubMed ID: 38366141
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 Delta infection.
    Routhu NK; Gangadhara S; Lai L; Davis-Gardner ME; Floyd K; Shiferaw A; Bartsch YC; Fischinger S; Khoury G; Rahman SA; Stampfer SD; Schäfer A; Jean SM; Wallace C; Stammen RL; Wood J; Joyce C; Nagy T; Parsons MS; Gralinski L; Kozlowski PA; Alter G; Suthar MS; Amara RR
    Sci Immunol; 2022 Jun; 7(72):eabo0226. PubMed ID: 35357886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Humoral immune response after different SARS-CoV-2 vaccination regimens.
    Rose R; Neumann F; Grobe O; Lorentz T; Fickenscher H; Krumbholz A
    BMC Med; 2022 Jan; 20(1):31. PubMed ID: 35057798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
    Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
    Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models.
    Hajnik RL; Plante JA; Liang Y; Alameh MG; Tang J; Bonam SR; Zhong C; Adam A; Scharton D; Rafael GH; Liu Y; Hazell NC; Sun J; Soong L; Shi PY; Wang T; Walker DH; Sun J; Weissman D; Weaver SC; Plante KS; Hu H
    Sci Transl Med; 2022 Sep; 14(662):eabq1945. PubMed ID: 36103514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Waning immune responses against SARS-CoV-2 variants of concern among vaccinees in Hong Kong.
    Peng Q; Zhou R; Wang Y; Zhao M; Liu N; Li S; Huang H; Yang D; Au KK; Wang H; Man K; Yuen KY; Chen Z
    EBioMedicine; 2022 Mar; 77():103904. PubMed ID: 35248996
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees.
    Jäger M; Sonnleitner ST; Dichtl S; Lafon E; Diem G; Walder G; Lass-Flörl C; Wilflingseder D; Posch W
    Front Immunol; 2022; 13():868361. PubMed ID: 35833113
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous ChAdOx1 nCoV-19 and BNT162b2 prime-boost vaccination elicits potent neutralizing antibody responses and T cell reactivity against prevalent SARS-CoV-2 variants.
    Groß R; Zanoni M; Seidel A; Conzelmann C; Gilg A; Krnavek D; Erdemci-Evin S; Mayer B; Hoffmann M; Pöhlmann S; Liu W; Hahn BH; Beil A; Kroschel J; Jahrsdörfer B; Schrezenmeier H; Kirchhoff F; Münch J; Müller JA
    EBioMedicine; 2022 Jan; 75():103761. PubMed ID: 34929493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing Antibodies Response against SARS-CoV-2 Variants of Concern Elicited by Prior Infection or mRNA BNT162b2 Vaccination.
    Bonura F; Genovese D; Amodio E; Calamusa G; Sanfilippo GL; Cacioppo F; Giammanco GM; De Grazia S; Ferraro D
    Vaccines (Basel); 2022 May; 10(6):. PubMed ID: 35746482
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
    Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
    Front Immunol; 2022; 13():863554. PubMed ID: 35711445
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Heterogeneous SARS-CoV-2-Neutralizing Activities After Infection and Vaccination.
    Graninger M; Camp JV; Aberle SW; Traugott MT; Hoepler W; Puchhammer-Stöckl E; Weseslindtner L; Zoufaly A; Aberle JH; Stiasny K
    Front Immunol; 2022; 13():888794. PubMed ID: 35711424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omicron BA.1 Mutations in SARS-CoV-2 Spike Lead to Reduced T-Cell Response in Vaccinated and Convalescent Individuals.
    Emmelot ME; Vos M; Boer MC; Rots NY; de Wit J; van Els CACM; Kaaijk P
    Viruses; 2022 Jul; 14(7):. PubMed ID: 35891550
    [TBL] [Abstract][Full Text] [Related]  

  • 20. T Cell Response following Anti-COVID-19 BNT162b2 Vaccination Is Maintained against the SARS-CoV-2 Omicron B.1.1.529 Variant of Concern.
    Cohen H; Rotem S; Elia U; Bilinsky G; Levy I; Chitlaru T; Bar-Haim E
    Viruses; 2022 Feb; 14(2):. PubMed ID: 35215940
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.